EBV BRLF1 (148-156) (HLA-A3)
Ref. 3D-CRB1001457
| 1mg | 271.00 € | ||
| 500µg | 198.00 € |
Product Information
- H-RVRAYTYSK-OH
EBV BRLF1 (148-156) (HLA-A3) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and the consequent death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV BRLF1 (148-156) (HLA-A3) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-A3 refers to the cell HLA type that this peptide acts on.The BRLF1 protein is a transcriptional activator that interacts with the amino and carboxy termini of the CREB-binding protein (CBP). CBP activates the lytic EBV gene SM, meaning the interaction between CBP and BRLF1 is responsible for EBV particles switching from latent to lytic viral replication.
Chemical properties
Technical inquiry about: 3D-CRB1001457 EBV BRLF1 (148-156) (HLA-A3)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
